Tesamorelin

DRUG13 trials

Conditions

Abdominal ObesityAgingBody CompositionChronic Obstructive Pulmonary Disease (COPD)Diabetic RetinopathyFatty LiverFrailtyGrowth Hormone Deficiency

Phase 1

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

CompletedNCT02012556

TheratechnologiesHIV

Start: 2008-05-31End: 2008-07-31Updated: 2013-12-16

Phase 2

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

TerminatedNCT01388920

TheratechnologiesChronic Obstructive Pulmonary Disease (COPD)

Start: 2011-09-30End: 2011-12-31Updated: 2022-03-18

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

CompletedNCT02572323

University of California, San DiegoMild Cognitive Impairment

Start: 2017-02-15End: 2023-10-15Updated: 2026-03-12

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

WithdrawnNCT02931474

National Institute of Nursing Research (NINR)Sleep Disorder, Traumatic Brain Injury

Start: 2016-10-06End: 2017-03-08Updated: 2019-11-19

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

CompletedNCT03375788

Massachusetts General HospitalFatty Liver, Liver Fat, Non-Alcoholic Fatty Liver Disease +2

Start: 2019-01-17End: 2025-01-10Updated: 2025-11-20

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

RecruitingNCT06554717

Massachusetts General HospitalAbdominal Obesity, Aging, Frailty +2

Start: 2025-07-07End: 2028-06-30Target: 100Updated: 2025-07-29

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

RecruitingNCT07481734

Hudson BiotechHepatic Steatosis, Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis

Start: 2026-02-02End: 2028-02-17Target: 120Updated: 2026-03-19

Phase 3

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

CompletedNCT00608023

TheratechnologiesHIV Infections, Lipodystrophy

Start: 2007-08-31End: 2008-10-31Updated: 2022-09-30

Phase 4

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

TerminatedNCT01591902

TheratechnologiesDiabetic Retinopathy, HIV

Start: 2012-06-30End: 2018-08-31Updated: 2018-09-11

Body Composition and Adipose Tissue in HIV

CompletedNCT03226821

Columbia UniversityBody Composition, Growth Hormone Deficiency, HIV Lipodystrophy Syndrome

Start: 2018-02-07End: 2025-04-30Updated: 2025-05-13

Unknown Phase

Effects of Growth Hormone Releasing Hormone in HIV

CompletedNCT01263717

Massachusetts General HospitalHIV, HIV Lipodystrophy

Start: 2010-12-31End: 2014-02-28Updated: 2017-10-30

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

WithdrawnNCT01632592

Massachusetts General HospitalAbdominal Obesity

Start: 2014-01-31End: 2014-01-31Updated: 2014-01-24

Tesamorelin Effects on Liver Fat and Histology in HIV

CompletedNCT02196831

Massachusetts General HospitalHuman Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)

Start: 2015-07-01End: 2019-07-24Updated: 2020-01-27

Related Papers

Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach.

2021-05-188 citations

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease

Clinical Infectious Diseases2021-01-1313 citations

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

2019-10-1159 citations

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

2017-10-078 citations

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation

JAMA2014-07-1983 citations

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

2012-04-1023 citations